• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    8/30/23 9:06:10 AM ET
    $ACOR
    $AEON
    $AHG
    $ARAV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • NanoVibronix (NASDAQ:NAOV) stock increased by 71.0% to $2.48 during Wednesday's pre-market session. The company's market cap stands at $4.1 million.
    • Aravive (NASDAQ:ARAV) stock moved upwards by 21.13% to $0.14. The market value of their outstanding shares is at $10.6 million.
    • Dermata Therapeutics (NASDAQ:DRMA) stock increased by 18.81% to $1.2. The company's market cap stands at $3.8 million.
    • AEON Biopharma (AMEX:AEON) stock rose 14.17% to $4.59. The company's market cap stands at $170.5 million.
    • Akso Health Group (NASDAQ:AHG) shares increased by 12.01% to $0.82. The company's market cap stands at $18.6 million.
    • Harvard Bioscience (NASDAQ:HBIO) stock moved upwards by 11.96% to $4.96. The company's market cap stands at $211.7 million.

    Losers

    • Outlook Therapeutics (NASDAQ:OTLK) stock decreased by 78.3% to $0.31 during Wednesday's pre-market session. The company's market cap stands at $79.5 million.
    • FibroGen (NASDAQ:FGEN) stock declined by 24.61% to $0.96. The market value of their outstanding shares is at $94.7 million.
    • OKYO Pharma (NASDAQ:OKYO) stock decreased by 12.83% to $2.65. The market value of their outstanding shares is at $67.7 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares declined by 11.75% to $2.63. The company's market cap stands at $3.8 million.
    • LENSAR (NASDAQ:LNSR) stock declined by 11.72% to $3.09. The market value of their outstanding shares is at $34.7 million.
    • Acorda Therapeutics (NASDAQ:ACOR) stock decreased by 11.64% to $11.24. The company's market cap stands at $13.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AEON
    $AHG
    $ARAV

    CompanyDatePrice TargetRatingAnalyst
    LENSAR Inc.
    $LNSR
    3/18/2026$10.00Neutral → Buy
    BTIG Research
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    8/28/2025Buy → Neutral
    Guggenheim
    Harvard Bioscience Inc.
    $HBIO
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Outlook Therapeutics Inc.
    $OTLK
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    Outlook Therapeutics Inc.
    $OTLK
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $ACOR
    $AEON
    $AHG
    $ARAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jacob Gary S

    3 - OKYO Pharma Ltd (0001849296) (Issuer)

    3/18/26 8:37:54 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Cerrone Gabriele M

    3 - OKYO Pharma Ltd (0001849296) (Issuer)

    3/18/26 8:35:59 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Akso Health Group

    3 - Akso Health Group (0001702318) (Issuer)

    3/18/26 5:27:12 PM ET
    $AHG
    Real Estate

    $ACOR
    $AEON
    $AHG
    $ARAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammat

    3/19/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

    LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod (0.05%) for the treatment of NCP. This new quality-of-life (QoL) data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. The presentation, titled: "First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinic

    3/18/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

    Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by d

    3/16/26 4:57:00 PM ET
    $ALC
    $LNSR
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    $ACOR
    $AEON
    $AHG
    $ARAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Duke John D bought $25,050 worth of shares (5,000 units at $5.01), increasing direct ownership by 5% to 105,000 units (SEC Form 4)

    4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

    3/17/26 5:56:45 PM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane bought $33,750 worth of shares (3,700 units at $9.12), increasing direct ownership by 17% to 24,939 units (SEC Form 4)

    4 - FIBROGEN INC (0000921299) (Issuer)

    11/17/25 4:42:52 PM ET
    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AEON
    $AHG
    $ARAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LENSAR upgraded by BTIG Research with a new price target

    BTIG Research upgraded LENSAR from Neutral to Buy and set a new price target of $10.00

    3/18/26 8:19:03 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AEON
    $AHG
    $ARAV
    SEC Filings

    View All

    SEC Form 6-K filed by OKYO Pharma Limited

    6-K - OKYO Pharma Ltd (0001849296) (Filer)

    3/19/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by OKYO Pharma Limited

    6-K - OKYO Pharma Ltd (0001849296) (Filer)

    3/18/26 7:58:21 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure

    8-K - LENSAR, Inc. (0001320350) (Filer)

    3/17/26 8:26:20 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AEON
    $AHG
    $ARAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AEON Biopharma Inc.

    SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

    11/14/24 5:05:14 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AEON
    $AHG
    $ARAV
    Leadership Updates

    Live Leadership Updates

    View All

    AEON Biopharma Appoints John Bencich as Chief Financial Officer

    IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

    3/9/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    $ACOR
    $AEON
    $AHG
    $ARAV
    Financials

    Live finance-specific insights

    View All

    OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammat

    3/19/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC

    ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC ("Alcon") to terminate the merger agreement between the parties. We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unli

    3/16/26 4:30:00 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed CFO on Permanent BasisIntroduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a pivotal year for Harvard Bioscience as we strengthened our balance sheet and streamlined our operating model. This culminated in fourth quarter results

    3/12/26 7:30:00 AM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials